BRIEF published on 12/27/2024 at 07:05, 1 year 2 months ago Relief Therapeutics Updates on Potential Merger with Renexxion Strategic Partnership Biopharmaceuticals Relief Therapeutics Renexxion Merger Gastrointestinal Therapies
PRESS RELEASE published on 12/27/2024 at 07:00, 1 year 2 months ago Relief Therapeutics Provides Update on Potential Transaction with Renexxion Relief Therapeutics provides update on potential reverse merger with Renexxion, focusing on enhancing shareholder value and future growth opportunities in gastrointestinal disorders therapies Merger Biopharmaceutical Relief Therapeutics Clinical-stage Renexxion
BRIEF published on 12/16/2024 at 07:05, 1 year 3 months ago Relief Therapeutics Reports Promising Outcomes from PKU GOLIKE Trial Biopharmaceutical Clinical Trial PKU GOLIKE Phenylketonuria Metabolic Control
PRESS RELEASE published on 12/16/2024 at 07:00, 1 year 3 months ago Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial Relief Therapeutics announces final readout of PKU GOLIKE clinical trial showing superior metabolic control during prolonged fasting in PKU patients. Results aim to promote awareness and adoption of PKU GOLIKE Clinical Trial Relief Therapeutics PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/13/2024 at 23:05, 1 year 3 months ago Relief Therapeutics to End SEC Reporting Obligations with Form 15F Filing OTCQB SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F
PRESS RELEASE published on 12/13/2024 at 23:00, 1 year 3 months ago Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Relief Therapeutics announces filing of Form 15F to terminate SEC reporting obligations, maintaining listing on SIX Swiss Exchange and U.S. over-the-counter market SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F U.S. OTCQB
BRIEF published on 11/11/2024 at 07:05, 1 year 4 months ago Relief Therapeutics Reports Positive Outcomes in RLF-TD011 Trial for Epidermolysis Bullosa Relief Therapeutics RLF-TD011 Clinical Trial Results Epidermolysis Bullosa Microbiome Diversity
PRESS RELEASE published on 11/11/2024 at 07:00, 1 year 4 months ago Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Relief Therapeutics reports positive final results from RLF-TD011 clinical trial for Epidermolysis Bullosa, showing effective wound healing and microbiome diversity improvements Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
BRIEF published on 11/04/2024 at 07:05, 1 year 4 months ago Relief Therapeutics and Renexxion Consider Reverse Merger Biotechnology Shareholder Value Healthcare Reverse Merger Gastrointestinal Disorders
PRESS RELEASE published on 11/04/2024 at 07:00, 1 year 4 months ago Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger Relief Therapeutics signs non-binding letter of intent with Renexxion for reverse merger, aiming to create a combined entity with an expanded therapeutic pipeline Biopharmaceutical Relief Therapeutics Therapeutic Pipeline Reverse Merger Renexxion
Published on 03/18/2026 at 21:00, 2 hours 25 minutes ago PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie
Published on 03/18/2026 at 19:05, 4 hours 20 minutes ago Deposit Modeling at Thor Shows that the Proven Thor Epithermal Deposit is Flanked on Both Sides by a Much Larger Deposit
Published on 03/18/2026 at 18:10, 5 hours 15 minutes ago Silver X Mining Closes C$69M Brokered Private Placement of Secured Convertible Debentures
Published on 03/18/2026 at 14:30, 8 hours 55 minutes ago Ground Geophysics Underway at Murphy Lake, 5 km From Isoenergy's Hurricane Deposit, Athabasca Basin
Published on 03/18/2026 at 14:15, 9 hours 10 minutes ago Apex Provides Phase I Drilling Update at the Rift Rare Earth Project in Nebraska, U.S.A.
Published on 03/18/2026 at 22:00, 1 hour 25 minutes ago aap successfully completes MDR certification: All existing products approved according to MDR – market access in the EU and CE-relevant markets secured in the long term
Published on 03/18/2026 at 18:53, 4 hours 32 minutes ago EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Published on 03/18/2026 at 18:37, 4 hours 48 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/18/2026 at 18:15, 5 hours 9 minutes ago Northern Data Group releases audited FY 2025 Financial Results
Published on 03/18/2026 at 19:41, 3 hours 44 minutes ago Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 5 hours 25 minutes ago Deezer achieves profitability in FY25 as strategy delivers tangible results
Published on 03/18/2026 at 17:45, 5 hours 40 minutes ago Infotel : 2025 full-year results. Launch of a new Infotel 2030 strategic plan. Revenue target of €500 million by 2030.
